Company Introduction
A bio company owning antibody fragment-based technology and development innovative biologics

2020

03
Signed the agreement on joint R&D with Celros Biotech Co., Ltd. For double antibody development
02
Acquired an international patent (Canada) on SAFA technology

2019

12
Dec. Signed the agreement of IPO lead management with NH Investment Securities Co., Ltd.
Dec. Signed the agreement of CDMO with Samsung Biologics Co., Ltd.
07
July Approval of SAFA tropin IND filing for technology transfer for Ahn-gook Pharmacy Co., Ltd.

2018

09
Acquired an international patent (Japan) on SAFA technology 
05
Investment agreement from seven investors for Series A (KRW 7.5 billion)
01
Acquired an international patent (USA) on SAFA technology

2017

05
Investment agreement from four investors for Pre-Series A (KRW 3.0 billion)

2016

12
Established R&D Center at Chuncheon Bio Industry Promotion Agency

2015

12
SEED _ Investment agreement from two investors for SEED (KRW 2.3 billion)
SAFA technology Acquired an international patent (Korea) on SAFA technology
05
Signed the agreement for technology transfer for Ahn-gook Pharmacy Co., Ltd. on long-acting type hGH and G-CSF

2013

03
Acquired the certification of Venture Company
02
Established April Bio Co., Ltd.